Glaucoma treatment increases graft failure risk

Article

Escalating treatment for glaucoma patients who have undergone penetrating keratoplasty (PK) significantly increases the risk of graft failure and poor visual outcomes.

Escalating treatment for glaucoma patients who have undergone penetrating keratoplasty (PK) significantly increases the risk of graft failure and poor visual outcomes, according to a report published in the December 2007 issue of Ophthalmology.

Mansour Al-Mohaimeed, MD and colleagues from the King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia and the University of Iowa Hospitals and Clinics, Iowa City, USA reviewed the data for 715 eyes of 678 patients who had undergone PK at the King Khaled Eye Specialist Hospital over a two-year period. The prevalence and risk factors of escalation of glaucoma therapy and the effects on graft survival were evaluated.

Over a mean follow-up period of 32.2 months, treatment for glaucoma escalated in 89 eyes (12.4%). Medical escalation accounted for 73 (82%) cases and surgical escalation occurred in 16 (15%) eyes. The surgical indication for PK (p<0.001), increasing patient age (p<0.001), pre-existing glaucoma (p<0.001), recipient trephination (p=0.02) and being either pseudophakic or aphakic (p<0.001) were all significantly associated with an increased risk of glaucoma therapy escalation.

Eyes in which glaucoma therapy did escalate also had a significant reduction in graft survival, with 52.8% of grafts surviving among these eyes compared with 82.9% of eyes with treatment escalation. Furthermore, increased treatment for glaucoma significantly affected final visual acuity (VA). Just 9% of eyes in the escalated treatment group achieved a VA of 20/40 or better compared with 42.1% of eyes that did not require an increase in treatment.

The results of this study suggest that escalating treatment for glaucoma patients who have undergone PK, can significantly increase the risk of poor visual outcomes and graft failure.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.